Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145048 | 0.86 | MEN1 (0.31) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL145352 | 0.86 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL148300 | 0.84 | P2RX7 (0.38) | JAK2BTK | |
| SCHEMBL148801 | 0.84 | P2RX7 (0.38) | JAK2BTK | |
| SCHEMBL145684 | 0.82 | JAK2 (0.38) | JAK2BTK | |
| SCHEMBL148363 | 0.78 | JAK2 (0.39) | JAK2BTK | |
| SCHEMBL4097279 | 0.72 | ADRA2A (0.46) | ALDH1A1HPGDSMN1; SMN2ADRA2AADRA2B | |
| SCHEMBL124283 | 0.70 | ALDH1A1 (0.58) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL904810 | 0.68 | ADRA2C (0.41) | ALDH1A1HPGDSMN1; SMN2ADRA2AADRA2B | |
| SCHEMBL3689993 | 0.65 | P2RX7 (0.33) | ALDH1A1JAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | ALDH1A1 3832/4885HPGD 4175/4885SMN1; SMN2 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.